**Table S2 – Breakdown of isolate sources and antimicrobial susceptibility of 971 clinical isolates**

|  |  |
| --- | --- |
| Variable | # isolates (total = 971) |
| Isolate source |  |
| Lung | 443 (45.6%) |
| Urine/Catheter | 242 (24.9%) |
| ENT/Sinus | 144 (14.8%) |
| Skin/Wound | 96 (9.9%) |
| Blood | 26 (2.7%) |
| Other | 20 (2.1%) |
| Antimicrobial susceptibility  (n susceptible) |  |
| Amikacin† | 879 (90.5%) |
| Cefepime β | 850 (87.5%) |
| Ciprofloxacin¶ | 837 (86.2%) |
| Gentamicin† | 842 (86.7%) |
| Meropenem β | 820 (84.4%) |
| Piperacillinβ/Tazobactam‡ | 792 (81.6%) |
| Tobramycin† | 922 (95.0%) |
| Aztreonamβ\* | 640/751 (85.2%) |

\* Not all isolates had susceptibility data available for this antimicrobial

† Aminoglycoside

β Beta-lactam

¶ Fluoroquinolone

‡ Beta-lactamase inhibitor